A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related diseases. The
activation of the JAK/STAT pathway is related to abnormal proliferation, obstruction of
apoptosis, and differentiation disorder of leukemia cells which is caused by genetic
abnormalities and viral infection.